Abstract Number: 2440 • 2019 ACR/ARP Annual Meeting
Bone Mineral Density in Psoriatic Arthritis: Results from a Longitudinal Study
Background/Purpose: Evidence thus far on the effect of psoriatic arthritis (PsA) on bone mineral density (BMD) has been inconsistent. There is also insufficient guidance surrounding…Abstract Number: 2441 • 2019 ACR/ARP Annual Meeting
Rates of Treated Depression Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database
Background/Purpose: Depression is common among PsA patients, but rates may differ by PsA treatment. Our study compares rates of treated depression by PsA treatment type…Abstract Number: 2442 • 2019 ACR/ARP Annual Meeting
The Relationship Between Fatigue and Disease Activity as Determined by Different Indices in Patients with Psoriatic Arthritis (PsA)
Background/Purpose: Fatigue is a substantial problem in patients with psoriatic arthritis (PsA) that needs to be considered in the core set of domains. This study…Abstract Number: 2443 • 2019 ACR/ARP Annual Meeting
A Gender-based Analysis of Disease Activity and Its Relationship with Anxiety, Depression, Fatigue, and Fibromyalgia in Psoriatic Arthritis
Background/Purpose: This study sought to compare the disease activity and its relationship with anxiety, depression, fatigue, and fibromyalgia of patients with psoriatic arthritis (PsA) between…Abstract Number: 2444 • 2019 ACR/ARP Annual Meeting
Real-world Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Biologic Therapies
Background/Purpose: Though biologic therapies have demonstrated long-term response in randomized clinical trials for psoriatic arthritis (PsA), such patient populations and settings may not reflect the…Abstract Number: 2445 • 2019 ACR/ARP Annual Meeting
Enthesitis, Dactylitis, and Axial Disease in Psoriatic Arthritis (PsA): Impact on Patient Quality of Life and Work Productivity
Background/Purpose: PsA is a chronic, inflammatory disease characterised by peripheral arthritis, axial disease, dactylitis, enthesitis and skin and nail psoriasis. The impact of skin and…Abstract Number: 2446 • 2019 ACR/ARP Annual Meeting
Gender Differences in Psoriatic Arthritis – Impact on Tumor Necrosis Factor Inhibitors Persistence and Response
Background/Purpose: The impact of gender on tumor necrosis factor inhibitors (TNFi) effectiveness has been poorly studied in Psoriatic Arthritis (PsA) patients. The objective of this…Abstract Number: 2447 • 2019 ACR/ARP Annual Meeting
Characteristics of Psoriasis Patients with Subclinical Signs of Musculoskeletal Involvement Detected by Fluorescence Optical Imaging and Confirmed by MRI-assessment
Background/Purpose: Psoriasis (Pso) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to Pso whereas the…Abstract Number: 2448 • 2019 ACR/ARP Annual Meeting
Factors Associated with Discordance Between Patient and Rheumatologist Assessment of Disease Activity in Psoriatic Arthritis Considered in Remission
Background/Purpose: Assessment of disease activity in psoriatic arthritis (PsA) requires evaluation of multiple aspects and can be difficult. Perception of disease activity by patient and…Abstract Number: 2449 • 2019 ACR/ARP Annual Meeting
Assessing Risk of PsA Progression: Results from a Combined Psoriasis-PsA Center Cohort
Background/Purpose: About 30% of patients with skin psoriasis (PsO) develop psoriatic arthritis (PsA). The reasons for why only some progress to synovio-enthesial disease from skin…Abstract Number: 2450 • 2019 ACR/ARP Annual Meeting
The Paradoxical Effect of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center
Background/Purpose: Psoriatic arthritis (PsA) is a heterogenous inflammatory disease affecting skin, joints, and other domains. While psychiatric diseases (i.e., depression and anxiety) are known comorbidities,…Abstract Number: 2451 • 2019 ACR/ARP Annual Meeting
Rates of Myocardial Infarction, Stroke, and Revascularization Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk for cardiovascular (CV) events, but different treatment options may not have the same rates of…Abstract Number: 2452 • 2019 ACR/ARP Annual Meeting
The Performance of a Multi-marker Genetic Test to Identify Patients with Psoriatic Arthritis Among Psoriasis Patients
Background/Purpose: Improved understanding of the complex genetic architecture of PsA along with the reduction in the cost of genetic testing provide an opportunity to assess…Abstract Number: 2453 • 2019 ACR/ARP Annual Meeting
Static and Longitudinal Construct Validity of PROMIS CAT and Profile29 for Assessing Pain Interference, Physical Function and Fatigue in Psoriatic Arthritis
Background/Purpose: Pain, physical function and fatigue are outcomes reported as having the greatest importance to people with psoriatic arthritis (PsA)1,2. We assessed these outcomes in…Abstract Number: 2454 • 2019 ACR/ARP Annual Meeting
PROMIS Profile29 Differentiates Active Disease from Treat-to-Target State in Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) symptoms and quality of life are core domains for PsA assessment1. The PROMIS Profile29 measures symptoms and quality of life using…
- « Previous Page
- 1
- …
- 919
- 920
- 921
- 922
- 923
- …
- 2425
- Next Page »